Contineum Therapeutics (CTNM) Earnings Date, Estimates & Call Transcripts

Contineum Therapeutics logo
$8.65 -0.39 (-4.36%)
As of 03:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Contineum Therapeutics Earnings Summary

Contineum Therapeutics issued Q3 2026 earnings on November 3, 2026, reporting an EPS of -$0.49, which missed the consensus estimate of -$0.45 by $0.04. With a trailing EPS of -$1.77, Contineum Therapeutics' earnings are expected to decrease next year, from ($1.76) to ($1.85) per share.

Latest Q3
Earnings Date
Nov. 3Estimated
Consensus EPS
(Nov. 3)
-$0.45
Actual EPS
(Nov. 3)
-$0.49 Missed By -$0.04

Q3 2026 Earnings Resources

Get Contineum Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

CTNM Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Contineum Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$0.76-$0.36-$0.56
Q2 20262-$0.79-$0.36-$0.58
Q3 20262-$0.43-$0.35-$0.39
Q4 20262-$0.85-$0.35-$0.60
FY 20268-$2.83-$1.42-$2.13

Contineum Therapeutics Earnings History by Quarter

Report Date
0 Results
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026-$0.4538-$0.49 -$0.0363-$0.49$5.65M-
7/30/2026Q2 2026-$0.4488-$0.40+$0.0488-$0.40--
5/5/2026Q1 2026-$0.55-$0.39+$0.16-$0.39--
3/5/2026Q4 2025-$0.50-$0.49+$0.01-$0.49$5.00M-
10/30/2025Q3 2025-$0.58-$0.45+$0.13-$0.45$6.00M-
8/5/2025Q2 2025-$0.56-$0.62 -$0.06-$0.62$7.50M-
5/14/2025Q1 2025-$0.56-$0.62 -$0.06-$0.62$7.50M-

Contineum Therapeutics Earnings - Frequently Asked Questions

Contineum Therapeutics (NASDAQ:CTNM) last announced its quarterly earning data on Tuesday, November 3, 2026. Learn more on CTNM's earnings history.

In the previous quarter, Contineum Therapeutics (NASDAQ:CTNM) missed the analysts' consensus estimate of ($0.45) by $0.04 with a reported earnings per share (EPS) of ($0.49). Learn more on analysts' earnings estimate vs. CTNM's actual earnings.

Contineum Therapeutics (NASDAQ:CTNM) has a recorded net income of -$59.98 million. CTNM has generated -$1.77 earnings per share over the last four quarters.

Contineum Therapeutics' earnings are expected to decrease from ($1.76) per share to ($1.85) per share in the next year.


Earnings data for NASDAQ:CTNM is sourced from Fiscal.ai, with the most recent quarter reported on 11/3/2026. New results are added as companies report their earnings.
From Our Partners